Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
Bone is the most frequent site of metastases of prostate cancer and is almost always the first and frequently the only site of metastases where disease will progress to stage D3. In addition, the number of skeletal metastatic foci is the most powerful independent prognostic factor of limited response to hormone ablation therapy and poor survival of patients with advanced prostate cancer. Furthermore, disease progression frequently occurs in the osteoblastic metastases, even though androgen ablation therapy still provides adequate and sustained control of disease at the primary site. Notably, the management of metastatic disease onto bones has traditionally relied on therapeutic modalities, which almost exclusively aim at directly inducing cancer cell death. However, accumulating pieces of evidence, from both the clinical and the basic research front, point to major limitations of this conventional approach. The in vivo response of malignant cells to anticancer therapies is directly influenced by the local microenvironment in which they metastasize. In particular, organ sites frequently involved in metastatic diseases, such as the bones, appear to confer to metastatic cells protection from anticancer drug-induced apoptosis. This protection is mediated by soluble growth factors and cytokines released by the normal cellular constituents of the host tissue microenvironment. The characterization of bone microenvironment-related survival factors has led to the development of a novel hormone manipulation which can re-introduce clinical responses in patients with stage D3 prostate cancer.
Bogdanos
J
J
Department of Experimental Physiology, Medical School, University of Athens, 75 Micras Asias, Goudi-Athens, 115 27 Greece.
Karamanolakis
D
D
Tenta
R
R
Tsintavis
A
A
Milathianakis
C
C
Mitsiades
C
C
Koutsilieris
M
M
D000726:Androgen Antagonists / Q000627:therapeutic use; D059002:Androgen Receptor Antagonists; D000728:Androgens / Q000378:metabolism*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019898:Autocrine Communication / Q000502:physiology*; D001859:Bone Neoplasms / Q000378:metabolism* / Q000556:secondary; D001842:Bone and Bones / Q000502:physiology; D002470:Cell Survival; D019008:Drug Resistance, Neoplasm; D004703:Endocrine System / Q000502:physiology*; D004777:Environment; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D019899:Paracrine Communication / Q000502:physiology*; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D011944:Receptors, Androgen / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology
D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D000728:Androgens; D000970:Antineoplastic Agents; D011944:Receptors, Androgen; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1